Skip to main content
Klaus Lindpaintner, MD, Medical Genetics, South San Francisco, CA

KlausLindpaintnerMD

Medical Genetics South San Francisco, CA

CMO/CSO Intervenn Biosciences

Dr. Lindpaintner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lindpaintner's full profile

Already have an account?

  • Office

    InterVenn Biosciences
    2 Tower Place
    South San Francisco, CA 94080

Education & Training

  • University of Iowa Hospitals and Clinics
    University of Iowa Hospitals and ClinicsFellowship, Cardiovascular Disease, 1989 - 1990
  • University of Iowa Hospitals and Clinics
    University of Iowa Hospitals and ClinicsFellowship, Cardiovascular Disease, 1984 - 1986
  • Leopold Franzen University Innsbruck Faculty of Medicine
    Leopold Franzen University Innsbruck Faculty of MedicineClass of 1979

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2022 - 2026
  • MI State Medical License
    MI State Medical License 1981 - 2026
  • MA State Medical License
    MA State Medical License 1990 - 2025
  • IA State Medical License
    IA State Medical License 1984 - 1993
  • OH State Medical License
    OH State Medical License 1982 - 1984
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Cardiovascular Disease

Publications & Presentations

PubMed

Press Mentions

  • InterVenn’s Glycoproteomic-Based Biomarker Signature Successfully Predicts Favorable Outcomes in Metastatic Malignant Melanoma Patients Treated with Checkpoint Inhibitors
    InterVenn’s Glycoproteomic-Based Biomarker Signature Successfully Predicts Favorable Outcomes in Metastatic Malignant Melanoma Patients Treated with Checkpoint InhibitorsApril 12th, 2021
  • InterVenn Receives Foundational Patent, CLIA Lab Certification to Develop Clinical Glycoproteomics Solutions
    InterVenn Receives Foundational Patent, CLIA Lab Certification to Develop Clinical Glycoproteomics SolutionsJanuary 13th, 2021
  • InterVenn Biosciences Reports Results on Vista™ : A Multi-Indication Liquid Biopsy Research Panel Built on Glycoproteomics
    InterVenn Biosciences Reports Results on Vista™ : A Multi-Indication Liquid Biopsy Research Panel Built on GlycoproteomicsNovember 10th, 2020
  • Join now to see all

Grant Support

  • Automated Sequencing And Genotyping FacilityNational Center For Research Resources1997
  • Genetics Of Cerebrovascular DiseaseNational Heart, Lung, And Blood Institute1995–1997
  • Genetics Of Cerebrovascular DiseaseNational Heart, Lung, And Blood Institute1995–1996
  • Genetics Of Cerebrovascular DiseaseNational Heart, Lung, And Blood Institute1994